science wire



Results 1251 - 1300 of 1501.

Pharmacology - Health - 12.10.2012
New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months
New analysis of two large Phase III studies demonstrates a significant early treatment effect of Gilenya on relapses and MRI outcomes, including brain volume loss, in MS patients Data show generally higher adherence rates for once-daily oral Gilenya than injectable DMTs and positive real-world experience Pooled analysis of core and long-term study data from over 3,500 patients reinforce known safety profile; more than 49,000 patients treated as

Pharmacology - Health - 01.10.2012
Novartis receives European Commission approval for once-daily Seebri Breezhaler as maintenance COPD treatment in the EU
Seebri Breezhaler 44 mcg delivered dose approved for maintenance treatment of COPD will be available to patients and physicians in some EU markets by year-end In GLOW trials, Seebri Breezhaler improved lung function, reduced shortness of breath, reduced exacerbations, and improved quality of life up to 52 weeks versus placebo , , GLOW2 study showed Seebri Breezhaler provided 24-hour bronchodilation and is superior to placebo and similar to open

Health - Pharmacology - 27.09.2012
Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe plaque psoriasis
Phase II data show AIN457 given weekly during the first month of treatment improved hand/foot psoriasis at Week 12 (54% of patients vs 19% on placebo) AIN457 selectively binds to and inhibits interleukin-17A, a key driver of immune-mediated diseases and a promising target for the next generation of therapy[2-4] AIN457 pivotal Phase III trials with more than 3,000 psoriasis patients on track with regulatory submissions expected in 2013 Psoriasis

Health - Pharmacology - 24.09.2012
Results from Novartis Phase III study show that RLX030 reduced deaths in patients with acute heart failure
RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and showed RLX030 (serelaxin) was well tolerated Six-month study shows that investigational RLX030 reduced all-cause mortality in patients with acute heart failure (AHF) Results of single Phase III clinical trial to be discussed with health authorities worldwide Basel, September 24, 2012 - Phase III study results show that investigational RLX030 (serelaxin) reduced all-cause mortality in patients with acute heart failure (AHF) .

Health - Pharmacology - 21.09.2012
Novartis announces two CHMP positive opinions
Positive opinion for the use of vildagliptin, with or without metformin, in combination with a stable dose of insulin Additional positive opinion for the use of vildagliptin in combination with a sul

Health - Pharmacology - 21.09.2012
Novartis drug Votubia recommended by CHMP for EU approval
Votubia (everolimus) would be the first non-surgical treatment option in the EU for kidney tumors associated with tuberous sclerosis complex (TSC) Kidney tumors, or renal angiomyolipomas, affect up t

Health - Pharmacology - 05.09.2012
New data for Novartis drug Lucentis confirms long-term efficacy and safety profile and benefits of individualized treatment
REPAIR study shows an average of three Lucentis injections improve visual acuity in patients with myopic choroidal neovascularization RESTORE extension study demonstrates DME patients fully maintained initial vision gains with an average of 13.9 Lucentis injections over three years Retrospective analysis reinforces Lucentis well-characterized safety profile in wet AMD; ongoing LUMINOUS TM program now involves over 10,000 patients Basel, S

Pharmacology - Health - 03.09.2012
Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149
QVA149 demonstrated superior bronchodilation compared to indacaterol 150 mcg, glycopyrronium 50 mcg, salmeterol/fluticasone 50/500 mcg BID, OL tiotropium 18 mcg and placebo , Seebri Breezhaler (glycopyrronium bromide) demonstrated rapid, sustained bronchodilation and reduced exacerbations similar to OL tiotropium 18 mcg in GLOW pooled data analysis , Onbrez Breezhaler (indacaterol maleate) was superior to OL tiotropium 18 mcg in improving severe

Pharmacology - Health - 30.08.2012
Novartis QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year
SPARK demonstrated QVA149 statistically significantly reduced rate of moderate-to-severe exacerbations compared to glycopyrronium 50 mcg Study showed QVA149 statistically significantly reduced overall exacerbation rates compared to glycopyrronium 50 mcg and open-label tiotropium 18 mcg Basel, August 30, 2012 - Novartis announced today that the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler ) .

Pharmacology - Health - 29.08.2012
Novartis International BioCamp Highlights Global R&D Reach to Meet Patient Needs in Emerging Markets
International e vent brings 60 university students from 21 countries and territories to Novartis headquarters in Basel, Switzerland Dynamic BioC amp program engages students around scientific advance

Pharmacology - Health - 28.08.2012
Novartis drug Jakavi first medication to receive European Commission approval to treat patients with myelofibrosis
Jakavi (INC424, ruxolitinib) approval based on results from the most extensive myelofibrosis clinical trial program to date Myelofibrosis is a life-threatening blood cancer associated with progressiv

Pharmacology - Health - 26.08.2012
New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure
PARAMOUNT study shows LCZ696 reduced a key predictor of morbidity and mortality in patients with a common form of heart failure called HF-PEF , Up to half of the 20 million Europeans and Americans diagnosed with heart failure have HF-PEF - , leading to reduced life expectancy and frequent hospitalization - No therapies are currently approved to reduce morbidity and mortality in patients with HF-PEF, or heart failure with preserved ejection fract

Health - Pharmacology - 15.08.2012
Phase III results published in NEJM show ocriplasmin could be first pharmacological eye treatment for vitreomacular adhesion patients
Vitreomacular adhesion is an age-related progressive, debilitating eye disease, often leading to blindness; standard of care is "watchful waiting" or surgery Phase III results show that ocriplasmin significantly (p<0.001) resolved vitreomacular traction and closed macular holes compared to placebo For the majority of patients with resolution of vitreomacular adhesion after ocriplasmin administration, the resolution was achieved within

Health - Pharmacology - 06.08.2012
Novartis and University of Pennsylvania form broad-based R&D alliance to advance novel T-cell immunotherapies to treat cancer
Novartis and Penn enter into multi-year collaboration to study chimeric antigen receptor (CAR) technology for the treatment of cancer Pilot trial of first CAR investigational therapy, CART-19, shows two patients with advanced chronic lymphocytic leukemia in remission after more than a year , Novartis licenses worldwide rights to CART-19 from Penn and obtains worldwide commercial rights to products from the collaboration Basel, August 6, 2012 - N

Health - Pharmacology - 30.07.2012
Novartis drug Afinitor approved by European Commission to treat patients with the most common form of advanced breast cancer
In combination with exemestane, Afinitor is approved for use in women with HR+/HER2- advanced breast cancer after progressing on an aromatase inhibitor Approval is based on Phase III trial of more th

Health - Pharmacology - 20.07.2012
Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease
Approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago In a Phase III trial, Afinitor plus exeme

Pharmacology - Life Sciences - 25.06.2012
A new dimension for cell culture
The system developed by QGel allows for new tests of anti-cancer medication and novel experimentation in tissue engineering and regenerative medicine. Cancer cells and stem cells can now be cultivated in 3 dimensions to serve in various experiments to great advantage for researchers. This matrix, commercialized by the start-up QGel, which is based in the scientific park at Ecublens, offers the cells a similar environment to a living organism and is adaptable to the needs of the researcher.

Health - Pharmacology - 22.06.2012
Novartis receives positive CHMP opinion for once-daily Seebri Breezhaler to treat COPD patients in the EU
COPD patients in Phase III GLOW trials experienced improved lung function, reduced shortness of breath, reduced exacerbations, and improved quality of life , , , GLOW2 study showed Seebri Breezhaler provided 24-hour bronchodilation and was superior to placebo and similar to open-label tiotropium in improving lung function Seebri Breezhaler is the latest innovation in the Novartis COPD portfolio and when approved will offer patients an alternativ

Health - Pharmacology - 22.06.2012
CHMP recommends Novartis drug Afinitor for EU approval marking major milestone in the treatment of advanced breast cancer
Upon approval, Afinitor will provide a new treatment approach for women with HR+ advanced breast cancer, where there remains a significant unmet need In a Phase III trial, women taking Afinitor with

Pharmacology - Health - 22.06.2012
New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche’s Perjeta
Basel, June 22, 2012   New data from Phase III study showed that people with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta Roche announced today that people with HER-2 posi

Pharmacology - Health - 11.06.2012
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
Basel, 11 June, 2012 FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer New personalised medicine gives people with aggressive form of breast cancer more time wi

Pharmacology - Health - 11.06.2012
Novartis drug Gilenya shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Data from single-arm extension of head-to-head TRANSFORMS study show sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years Reductions in relapses and MRI measures were observed in patients who switched from Avonex (interferon-beta-1a IM) to Gilenya for study extension phase Extension study results demonstrated once-daily oral Gilenya was generally well-tolerated with

Health - Pharmacology - 06.06.2012
Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment
Data also showed one third of patients became steroid-free within five months with ACZ885 , a fully human monoclonal antibody that inhibits IL-1 beta ACZ885 regulatory submissions on track for 2012 i

Health - Pharmacology - 31.05.2012
Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer
18-month BOLERO-2 data confirm Afinitor combined with exemestane delays time without tumor growth for women with HR+ advanced breast cancer Data highlighted by ASCO show twice as many Ph+ CML-CP patients achieved deeper levels of response with Tasigna compared to imatinib , Earl y data on pipeline compounds demonstrate potential in breast cancer, non-small cell lung cancer, NRAS-mutated melanoma and other solid tumors Basel, May 31, 2012 - Novar

Pharmacology - Health - 17.05.2012
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients
GLOW2 study showed NVA237 superior to placebo and similar to open-label tiotropium in increasing lung function, improving COPD symptoms and reducing exacerbations , , Results demonstrated that once-daily NVA237 had rapid onset of action at first dose, sustained 24-hour bronchodilation, and was well tolerated over 52 weeks NVA237 submitted for EU approval under proposed brand name Seebri Breezhaler ; expect US filing in 2014 COPD is predicted to

Pharmacology - Health - 10.05.2012
New data among 200 Lucentis abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients
Data from key studies highlight the value of individualized therapy and reinforce Lucentis (ranibizumab) well-characterized long-term efficacy and safety profile RESTORE extension study in DME patients shows mean of 3.7 and 2.7 Lucentis injections required in years two and three, respectively, to maintain vision gains from core study Swiss retrospective study shows mean 8 letter VA gain sustained in wet AMD patients using individua

Health - Pharmacology - 07.05.2012
Novartis drug pasireotide LAR shows superior efficacy
Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care Acromegaly, a rare endocrine disorder caused

Business / Economics - Pharmacology - 02.05.2012
Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US
Acquisition of Fougera makes Sandoz, the generics division of Novartis, the number one generic dermatology medicines company globally and in the US, strengthening Sandoz's differentiated products str

Health - Pharmacology - 26.04.2012
Novartis drug Afinitor approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
Kidney tumors affect up to 80% of patients with tuberous sclerosis complex (TSC) and growing tumors may lead to unpredictable life-threatening complications Prior to the approval of Afinitor, surgica

Health - Pharmacology - 25.04.2012
Novartis drug Signifor approved in the EU as the first medication to treat patients with Cushing’s disease
Signifor is first targeted approach for Cushing's disease, a debilitating endocrine disorder caused by an underlying pituitary tumor that triggers excess cortisol , , Majority of patients in the Phas

Health - Pharmacology - 24.04.2012
Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges
Sandoz faced a strong year-ago base with enoxaparin exclusivity and Consumer Health impacted by the suspension of production at the Lincoln, Nebraska manufacturing site Core operating income of USD 3&

Pharmacology - Health - 20.04.2012
Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients with the life-threatening blood cancer myelofibrosis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer Patients with myelofibrosis experience

Pharmacology - Health - 20.04.2012
Novartis updates US label on Gilenya following discussions with the FDA
Updated Gilenya label provides further guidance to healthcare providers regarding treatment initiation with Gilenya in MS patients in the United States Prescribing information includes patient select

Health - Pharmacology - 20.04.2012
Novartis confirms positive benefit-risk profile of Gilenya following CHMP review and label update recommendation
Revised label agreed between Novartis and the CHMP provides further guidance to healthcare providers regarding treatment initiation with Gilenya in MS patients in the EU Patients should have ECG before and six hours after the first-dose, with hourly b lood pressure and heart rate measures; Continuous ECG recommended Caution regarding use in patients who may be less tolerant of or are more likely to develop significantly slowed or abnormal heart

Pharmacology - Chemistry - 20.04.2012
The presence of water changes the structure of an antibiotic
The presence of water changes the structure of an antibiotic
EPFL chemists have shown how the three-dimensional shape of an antibiotic changes when it is in an aqueous environment. This could lead to a better understanding of how drugs interact with biological molecules. Like a key inserted into a lock, the molecules in drugs bind with and act upon biomolecules.

Health - Pharmacology - 19.04.2012
Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded; product information updated
Combination product Valturna to be voluntarily withdrawn from the US market as of July 20, 2012 Basel, Switzerland April 19, 2012 - Novartis announced today that the Tekturna labels have been updated

Pharmacology - Health - 19.04.2012
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
Results from open label phase III extension and 7-year phase II extension studies show sustained low disease activity on clinical and MRI measures in patients continuing on Gilenya (fingolimod) treatment Extension study results demonstrate a safety profile for Gilenya consistent with pivotal trials Data from FIRST study in more than 2,400 patients show overall low incidence of first dose bradycardia and conduction abnormalities at treatment init

Chemistry - Pharmacology - 17.04.2012
EPFL de doctorate award 2012 - Oleg Vechorkin
A Well-Defined Ni Pincer Catalyst for Cross Coupling of Non-Activated Alkyl Halides and Direct C-H Alkylation.

Business / Economics - Pharmacology - 06.04.2012
Roche disappointed with ISS recommendation
Roche disappointed with ISS recommendation Urges Illumina shareholders to vote the GOLD proxy card Roche released the following statement in response to a report issued by Institutional Shareholder Services ("ISS") recommending that shareholders of Illumina, Inc.

Health - Pharmacology - 02.04.2012
Novartis QVA149 Phase III COPD studies meet primary endpoints
QVA149, a bronchodilator with dual mode of action, is Novartis' third innovation in its Breezhaler Single Dose Dry Powder Inhaler COPD is predicted to be the third leading cause of death in the world

Health - Pharmacology - 28.03.2012
Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world’s cancer cell lines
Collaboration with the Broad Institute yields comprehensive encyclopedia of genetic and molecular information for nearly 1,000 cancer cell lines Basel, March 28, 2012 - Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development.

Health - Pharmacology - 27.03.2012
Study in JAMA reports significant survival benefit in certain GIST patients taking Novartis drug Glivec for three years after surgery
First large Phase III study to demonstrate significant survival benefits of extending treatment with Glivec for three years compare d to one year following surgery Important finding for treatment of KIT+ GIST patients who are at risk of recurrence following complete resection of primary tumor Basel, March 27, 2012 - The Journal of the American Medical Association (JAMA) today published a Phase III study that showed significant survival benefits

Health - Pharmacology - 16.03.2012
Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion
Symptomatic vitreomacular adhesion (VMA) is a progressive, debilitating eye disease, there is currently no pharmacological treatment available Phase III clinical data demonstrate resolution of sympto

Health - Pharmacology - 07.03.2012
Data in NEJM shows Novartis drug Signifor is first therapy to provide rapid, durable benefit for Cushing’s disease patients in Phase III study
Study met primary endpoint showing Signifor (pasireotide) normalized cortisol overproduction , a critical factor in controlling the debilitating endocrine disorder , , Cortisol levels decreased quickly in the majority of patients and levels were normalized in 26.3% of patients treated with pasireotide 900µg twice daily Results showed pasireotide improved key clinical manifestations of the disease, including reductions in blood pressure, c

Health - Pharmacology - 02.03.2012
Reprogramming tumor-promoting macrophages for anti-cancer therapy
Reprogramming tumor-promoting macrophages for anti-cancer therapy
Researchers who have recently established their laboratory at the EPFL School of Life Sciences have identified a small RNA molecule that limits the pro-tumoral functions of macrophages.

Pharmacology - Health - 29.02.2012
Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that severely impact quality of life and reduce survival These data provided the basis for worldwide regulatory filings with first actions expected in the second half of 2012 Basel, February 29, 2012 - The New England Jour

Health - Pharmacology - 27.02.2012
European Commission approves new label for Novartis drug Glivec
Approval based on Phase III study showing significant recurrence-free and overall survival after three years of adjuvant Glivec in adults with KIT+ GIST Adults with KIT+ GIST are at risk of recurrence following surgical removal of the primary tumor; extended treatment may delay onset of recurrence Basel, February 27, 2012 - Novartis announced today that the European Commission (EC) has approved an update to the Glivec (imatinib)* label to includ

Health - Pharmacology - 24.02.2012
Breaking Down Cancer's Defense for Future Vaccines
Breaking Down Cancer's Defense for Future Vaccines
Researchers at the EPFL have identified an important mechanism that could lead to the design of more effective cancer vaccines. Their discovery of a new-found role of the lymphatic system in tumour growth shows how tumours evade detection. Tumour cells present antigens or protein markers on their surfaces which make them identifiable to the host immune system.

Pharmacology - Health - 17.02.2012
Novartis to revise product information in the European Union for high blood pressure drug Rasilez following assessment by CHMP
CHMP concluded the risk-benefit review of Rasilez* (aliskiren) and confirmed it remains positive for the treatment of essential hypertension CHMP has requested that the Rasilez (aliskiren) product in

Pharmacology - Health - 13.02.2012
New immunotherapeutic agent for the treatment of Alzheimer's disease
New immunotherapeutic agent for the treatment of Alzheimer's disease
Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides.

This site uses cookies and analysis tools to improve the usability of the site. More information. |